Clinical and Laboratory Diagnostics of Cardiovascular Disease: Focus on Natriuretic Peptides and Cardiac Ischemia

References

• Gibler W. B. Evaluation of chest pain in the emergency department. Ann Intern Med 1995; 123((4))315–8
   PubMedGoogle Scholar
• Storrow A. B., Gibler W. B. Chest pain centers: diagnosis of acute coronary syndromes. Ann Emerg Med 2000; 35((5))449–61
   PubMedGoogle Scholar
• Falk E., Shah P. K., Fuster V. Coronary plaque disruption. Circulation 1995; 92((3))657–71
   PubMed Web of Science ®Google Scholar
• Cannon C. P., Hand M. H., Bahr R., Boden W. E., Christenson R., Gibler W. B. Critical pathways for management of patients with acute coronary syndromes: an assessment by the National Heart Attack Alert Program. Am Heart J 2002; 143((5))777–89
   PubMedGoogle Scholar
• Cannon C. P. Treatment algorithms and critical pathways for acute coronary syndromes. Semin Vasc Med 2003; 3((4))425–32
   PubMedGoogle Scholar
• Sudoh T., Kangawa K., Minamino N., Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988; 332((6159))78–81
   PubMedGoogle Scholar
• De lemos J. A., Mcguire D. K., Drazner M. H. B‐type natriuretic peptide in cardiovascular disease. Lancet 26 2003; 362((9380))316–22
   PubMedGoogle Scholar
• Mukoyama M., Nakao K., Hosoda K., Suga S., Saito Y., Ogawa Y. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991; 87((4))1402–12
   PubMedGoogle Scholar
• Ruskoaho H. Cardiac hormones as diagnostic tools in heart failure. Endocr Rev 2003; 24((3))341–56
   PubMedGoogle Scholar
• Kinnunen P., Vuolteenaho O., Ruskoaho H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching. Endocrinology 1993; 132((5))1961–70
   PubMedGoogle Scholar
• Yandle T. G., Richards A. M., Gilbert A., Fisher S., Holmes S., Espiner E. A. Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure. J Clin Endocrinol Metab 1993; 76((4))832–8
   PubMedGoogle Scholar
• Yamamoto K., Burnett J. C, Jr., Jougasaki M., Nishimura R. A., Bailey K. R., Saito Y. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996; 28((6))988–94
   PubMedGoogle Scholar
• Omland T., Aakvaag A., Bonarjee V. V., Caidahl K., Lie R. T., Nilsen D. W. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long‐term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N‐terminal proatrial natriuretic peptide. Circulation 1996; 93((11))1963–9
   PubMedGoogle Scholar
• Omland T., De lemos J. A., Morrow D. A., Antman E. M., Cannon C. P., Hall C. Prognostic value of N‐terminal pro‐atrial and pro‐brain natriuretic peptide in patients with acute coronary syndromes. Am J Cardiol 2002; 89((4))463–5
   PubMedGoogle Scholar
• De lemos J. A., Morrow D. A., Bentley J. H., Omland T., Sabatine M. S., Mccabe C. H. The prognostic value of B‐type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345((14))1014–21
   PubMedGoogle Scholar
• Kikuta K., Yasue H., Yoshimura M., Morita E., Sumida H., Kato H. Increased plasma levels of B‐type natriuretic peptide in patients with unstable angina. Am Heart J 1996; 132((1 Pt 1))101–7
   PubMedGoogle Scholar
• Talwar S., Squire I. B., Downie P. F., Davies J. E., Ng L. L. Plasma N terminal pro‐brain natriuretic peptide and cardiotrophin 1 are raised in unstable angina. Heart 2000; 84((4))421–4
   PubMedGoogle Scholar
• Omland T., Aakvaag A., Vik‐mo H. Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment. Heart 1996; 76((3))232–7
   PubMedGoogle Scholar
• Gerber I. L., Stewart R. A., Legget M. E., West T. M., French R. L., Sutton T. M. Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation 2003; 107((14))1884–90
   PubMedGoogle Scholar
• Sutton T. M., Stewart R. A., Gerber I. L., West T. M., Richards A. M., Yandle T. G. Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation. J Am Coll Cardiol 2003; 41((12))2280–7
   PubMedGoogle Scholar
• Hama N., Itoh H., Shirakami G., Nakagawa O., Suga S., Ogawa Y. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation 1995 Sep 15; 92((6))1558–64
   PubMedGoogle Scholar
• Jougasaki M., Yasue H., Mukoyama M., Nakao K., Takahashi K. Appearance of atrial natriuretic peptide in the ventricles in patients with myocardial infarction. Am Heart J 1990; 119((1))92–6
   PubMedGoogle Scholar
• Morita E., Yasue H., Yoshimura M., Ogawa H., Jougasaki M., Matsumura T. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 1993; 88((1))82–91
   PubMedGoogle Scholar
• Richards A. M., Nicholls M. G., Yandle T. G., Frampton C., Espiner E. A., Turner J. G. Plasma N‐terminal pro‐brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998; 97((19))1921–9
   PubMedGoogle Scholar
• Omland T., Persson A., Ng L., O'brien R., Karlsson T., Herlitz J. N‐terminal pro‐B‐type natriuretic peptide and long‐term mortality in acute coronary syndromes. Circulation 2002; 106((23))2913–8
   PubMedGoogle Scholar
• Richards A. M., Nicholls M. G., Espiner E. A., Lainchbury J. G., Troughton R. W., Elliott J. B‐type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 2003; 107((22))2786–92
   PubMedGoogle Scholar
• James S. K., Lindahl B., Siegbahn A., Stridsberg M., Venge P., Armstrong P. N‐terminal pro‐brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)‐IV substudy. Circulation 2003; 108((3))275–81
   PubMedGoogle Scholar
• Heeschen C., Hamm C. W., Mitrovic V., Lantelme N. H., White H. D. N‐terminal pro‐B‐type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation 2004; 110((20))3206–12
   PubMedGoogle Scholar
• Kyriakides Z. S., Markianos M., Michalis L., Antoniadis A., Nikolaou N. I., Kremastinos D. T. Brain natriuretic peptide increases acutely and much more prominently than atrial natriuretic peptide during coronary angioplasty. Clin Cardiol 2000; 23((4))285–8
   PubMedGoogle Scholar
• Tateishi J., Masutani M., Ohyanagi M., Iwasaki T. Transient increase in plasma brain (B‐type) natriuretic peptide after percutaneous transluminal coronary angioplasty. Clin Cardiol 2000; 23((10))776–80
   PubMedGoogle Scholar
• Marumoto K., Hamada M., Hiwada K. Increased secretion of atrial and brain natriuretic peptides during acute myocardial ischaemia induced by dynamic exercise in patients with angina pectoris. Clin Sci (Lond) 1995; 88((5))551–6
   PubMedGoogle Scholar
• Goetze J. P., Christoffersen C., Perko M., Arendrup H., Rehfeld J. F., Kastrup J. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J 2003 Jun; 17((9))1105–7
   PubMedGoogle Scholar
• Bibbins‐domingo K., Ansari M., Schiller N. B., Massie B., Whooley M. A. B‐type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study. Circulation 2003; 108((24))2987–92
   PubMedGoogle Scholar
• Sabatine M. S., Morrow D. A., De lemos J. A., Omland T., Desai M. Y., Tanasijevic M. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol 2004; 44((10))1988–95
   PubMedGoogle Scholar
• Omland T., Richards A. M., Wergeland R., Vik‐mo H. B‐type natriuretic peptide and long‐term survival in patients with stable coronary artery disease. Am J Cardiol 2005; 95((1))24–8
   PubMedGoogle Scholar
• Kragelund C., Gronning B., Kober L., Hildebrandt P., Steffensen R. N‐terminal pro‐B‐type natriuretic peptide and long‐term mortality in stable coronary heart disease. N Engl J Med 2005; 352((7))666–75
   PubMedGoogle Scholar
• Toth M., Vuorinen K. H., Vuolteenaho O., Hassinen I. E., Uusimaa P. A., Leppaluoto J. Hypoxia stimulates release of ANP and BNP from perfused rat ventricular myocardium. Am J Physiol 1994; 266((4 Pt 2))H1572–H1580
   Google Scholar
• D'souza S. P., Yellon D. M., Martin C., Schulz R., Heusch G., Onody A. B‐type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening. Am J Physiol Heart Circ Physiol 2003; 284((5))H1592–H1600
   Google Scholar
• Ruck A., Gustafsson T., Norrbom J., Nowak J., Kallner G., Soderberg M. ANP and BNP but not VEGF are regionally overexpressed in ischemic human myocardium. Biochem Biophys Res Commun 2004; 322((1))287–91
   PubMedGoogle Scholar
• D'souza S. P., Baxter G. F. B Type natriuretic peptide: a good omen in myocardial ischaemia?. Heart 2003; 89((7))707–9
   PubMedGoogle Scholar